Shares of Bright Minds Biosciences Inc. (DRUG) have gained 2.9% over the past four weeks to close the last trading session at $60.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $82.4 indicates a potential upside of 36.3%.The average comprises five short-term price targets ranging from a low of $72.00 to a high of $93.00, with a standard deviation of $7.64. While the lowest ...

Shares of Altimmune, Inc. (ALT) have gained 23.2% over the past four weeks to close the last trading session at $5.1, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.88 indicates a potential upside of 250.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.81. While the lowest estimate of $1.00 indicates a 80.4% decline from the curr ...

Core Viewpoint - Great Lakes Dredge & Dock (GLDD) shows potential for significant upside, with a mean price target of $15.67 indicating a 32.1% increase from the current price of $11.86 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $1.53, suggesting variability among analysts [2] - The lowest estimate of $14.00 indicates an 18% increase, while the highest target of $17.00 suggests a 43.3% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about GLDD's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 7.9% over the past month, with two estimates increasing and no negative revisions [12] - GLDD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely predict actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - LiveRamp (RAMP) shares have seen a 1% increase over the past four weeks, closing at $28.78, with a potential upside of 46.4% based on Wall Street analysts' mean price target of $42.14 [1][11]. Price Targets - The average price target consists of seven estimates ranging from a low of $33.00 to a high of $53.00, with a standard deviation of $7.8, indicating variability among analysts [2]. - The lowest estimate suggests a 14.7% increase from the current price, while the highest indicates an 84.2% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding RAMP's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 3.3%, with one estimate moving higher in the last 30 days and no negative revisions [12]. Zacks Rank - RAMP holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as analysts may set overly optimistic targets due to business incentives [3][8][10].

Core Viewpoint - Stagwell (STGW) shares have increased by 4.5% recently, with analysts suggesting a potential upside of 54.5% based on a mean price target of $8.25 [1][11]. Price Targets - The average price target from seven analysts ranges from a low of $6.50 to a high of $10.00, indicating a standard deviation of $1.18, which reflects the variability of estimates [2]. - The lowest estimate suggests a 21.7% increase from the current price, while the highest estimate indicates an 87.3% upside [2]. Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - Over the past 30 days, one estimate has increased, leading to a 4.8% rise in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - STGW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Caution on Price Targets - While price targets are a common metric, they can often mislead investors, and reliance solely on them for investment decisions may not be prudent [3][7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Core Viewpoint - LATAM (LTM) stock shows potential for upside, with a mean price target of $56.73 indicating a 25.2% increase from the current price of $45.33 [1] Price Targets - The average price target consists of four estimates ranging from $50.90 to $60.00, with a standard deviation of $4.32, suggesting a consensus among analysts [2] - The lowest estimate indicates a 12.3% increase, while the highest suggests a 32.4% upside [2] - A low standard deviation indicates greater agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about LTM's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 5.4%, with two estimates moving higher and no negative revisions [12] Zacks Rank - LTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Veritone, Inc. (VERI) has shown a downtrend recently, losing 7.9% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in a downtrend, characterized by a small candle body and a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern forms when a stock opens lower, makes a new low, but then finds support and closes near its opening price, indicating a possible shift in momentum [4][5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for VERI, with the consensus EPS estimate increasing by 12.3% over the last 30 days, indicating improved earnings potential [7][8]. - Wall Street analysts are optimistic about VERI's future earnings, which enhances the likelihood of a trend reversal for the stock [2][7]. Zacks Rank - VERI currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a turnaround [10].

Core Viewpoint - MediaAlpha, Inc. (MAX) shows potential for significant upside, with a mean price target of $15.93 indicating a 34.3% increase from its current price of $11.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $2.39, suggesting variability in analyst predictions [2] - The lowest estimate is $13.00, indicating a 9.6% increase, while the highest estimate is $19.00, suggesting a 60.2% increase [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about MAX's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, two estimates have increased, leading to a 5.6% rise in the Zacks Consensus Estimate for the current year [12] - MAX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - vTv Therapeutics (VTVT) has shown a significant price increase of 41.4% over the past four weeks, with a mean price target of $37 indicating a potential upside of 25.2% from the current price of $29.56 [1] Price Targets and Analyst Consensus - The average price target for VTVT ranges from a low of $35.00 to a high of $40.00, with a standard deviation of $2.65, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates an 18.4% increase, while the highest suggests a 35.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about VTVT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 9.2% over the past month, with no negative revisions reported [12] - VTVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can often mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Liquidia Corporation (LQDA) has shown a significant price increase of 30.1% over the past four weeks, with a mean price target of $44 indicating a potential upside of 51.2% from the current price of $29.11 [1] Price Targets and Analyst Consensus - The average price target for LQDA includes nine estimates ranging from a low of $16.00 to a high of $67.00, with a standard deviation of $14.33, indicating variability in analyst predictions [2] - The lowest estimate suggests a potential decline of 45%, while the highest indicates a possible upside of 130.2% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about LQDA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 50.8%, with five estimates moving higher and no negative revisions [12] - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]